CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jounce Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jounce Therapeutics Inc
780 Memorial Drive
Phone: (857) 259-3840p:857 259-3840 CAMBRIDGE, MA  02139  United States Fax: (617) 812-5345f:617 812-5345
This company ceased filing statements with the SEC on 5/15/2023.
On 5/3/2023, the Company was acquired by Concentra Biosciences, LLC.
This company is no longer actively traded on any major stock exchange.
Business Summary
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). It also develops JTX-1484 and JTX-2134 product candidates.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2022YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Perry A.Karsen 67 4/1/2016 1/1/2016
Interim President, Chief Financial Officer, Treasurer Kimberlee C.Drapkin 54 3/31/2023 2/1/2013
Director RichardMurray 63 3/31/2023 7/1/2014
3 additional Officers and Directors records available in full report.

Business Names
Business Name
JNCE
Jounce Mass Securities, Inc.

General Information
Number of Employees: 141 (As of 12/31/2022)
Outstanding Shares: 52,635,468 (As of 4/21/2023)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 454870634
Fax Number: (617) 812-5345


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024